EFFICACY AND SAFETY OF ADDITIONAL CYCLES OF DINUTUXIMAB BETA ADMINISTERED IN MAINTENANCE THERAPY IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 212; Pres time: Sep 17, 2026; Location: Exhibition Area; " Thirteen patients with HR-NB (8 males, age 0.85-100.8 months at diagnosis) received 1-10 additional DB cycles after maintenance, including 2 with chemotherapy and 1 with Nivolumab. Additional DB cycles appear effective and tolerated in patients with response and no CR after five cycles. Extending treatment may increase CR rates without increased toxicity. Larger studies are needed to confirm this benefit."
Clinical • Neuroblastoma • Solid Tumor
|
|
Urszula Zebrowska; Walentyna Balwierz; Szymon Skoczen; Aleksandra Wieczorek
|